Evidence map›Paper›PMID 27531258›Full record

ArticleExperimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie2016

Elevated connexin 43 expression in arsenite-and cadmium-transformed human bladder cancer cells, tumor transplants and selected high grade human bladder cancers.

Ruowen Zhang, Liping Wang, Scott H Garrett, Donald A Sens, Jane R Dunlevy, Xu Dong Zhou, Seema Somji

Open access · greenAbstract read
In one paragraph

Article in Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ruowen ZhangDepartment of Pathology, School of Medicine and Health Sciences, University of North Dakota 501N. Columbia Road, Grand Forks, ND 58203, United States. Electronic address: zrw0814@uab.edu.
Liping WangDepartment of Pathology, School of Medicine and Health Sciences, University of North Dakota 501N. Columbia Road, Grand Forks, ND 58203, United States. Electronic address: wlppping@126.com.
Scott H GarrettDepartment of Pathology, School of Medicine and Health Sciences, University of North Dakota 501N. Columbia Road, Grand Forks, ND 58203, United States. Electronic address: scott.garrett@med.und.edu.
Donald A SensDepartment of Pathology, School of Medicine and Health Sciences, University of North Dakota 501N. Columbia Road, Grand Forks, ND 58203, United States. Electronic address: donald.sens@med.und.edu.
Jane R DunlevyDepartment of Basic Sciences, School of Medicine and Health Sciences, University of North Dakota, 501N. Columbia Road, Grand Forks, ND 58203, United States. Electronic address: jane.dunlevy@med.und.edu.
Xu Dong ZhouDepartment of Pathology, School of Medicine and Health Sciences, University of North Dakota 501N. Columbia Road, Grand Forks, ND 58203, United States. Electronic address: xudong.zhou@med.und.edu.
Seema SomjiDepartment of Pathology, School of Medicine and Health Sciences, University of North Dakota 501N. Columbia Road, Grand Forks, ND 58203, United States. Electronic address: seema.somji@med.und.edu.
University of North Dakota · US

Funding

Research CoresP20GM103442 · NIGMS · UNIVERSITY OF NORTH DAKOTA · PI Chris Jurgens · 2012 to 2026
$53.0M
NIGMS NIH HHS P20 GM103442
6 · The paper itself

Abstract

Connexin 43 has been shown to play a role in cell migration and invasion; however, its role in bladder cancer is not well defined. Previous studies from our laboratory have shown that the environmental pollutants arsenite and cadmium can cause malignant transformation of the immortalized urothelial cell line UROtsa. These transformed cells can form tumors in immune-compromised mice. The goal of the present study was to determine if connexin 43 is expressed in the normal human bladder, the arsenite and cadmiun-transformed UROtsa cells as well as human urothelial cancer. The results obtained showed that connexin 43 is not expressed in the epithelial cells of the human bladder but is expressed in immortalized cultures of human urothelial cells and the expression is variable in the arsenite and cadmium- transformed urothelial cell lines derived from these immortalized cells. Tumor heterotransplants generated from the transformed cells expressed connexin 43 and the expression was localized to areas of squamous differentiation. Immuno-histochemical analysis of human bladder cancers also showed that the expression of connexin 43 was localized to areas of the tumor that showed early features of squamous differentiation. Treatment of UROtsa cells with various concentrations of arsenite or cadmium did not significantly alter the expression level of connexin 43. In conclusion, our results show that the expression of connexin 43 is localized to the areas of the tumor that show squamous differentiation, which may be an indicator of poor prognosis. This suggests that connexin 43 has the potential to be developed as a biomarker for bladder cancer that may have the ability to invade and metastasize.

Indexed as

AnimalsArsenitesBiomarkers, TumorCadmiumCarcinoma, Transitional CellCell Line, TumorCell Transformation, NeoplasticConnexin 43HeterograftsHumansImmunohistochemistryMiceMice, NudePolymerase Chain ReactionUrinary Bladder NeoplasmsarseniteArsenitesBiomarkers, TumorCadmiumConnexin 43GJA1 protein, humanArsenicCadmiumConnexin 43Squamous differentiationUrothelial cancerUROtsa

Identifiers

PMID27531258
PMCPMC5123665
OpenAlexW2515950950

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.